ATE243530T1 - Virus impfstoff - Google Patents

Virus impfstoff

Info

Publication number: ATE243530T1
Authority: AT; Austria
Prior art keywords: virus; strains; inactivated; neuraminidase; hemagglutinin
Prior art date: 1995-04-28

Application number

AT96913234T

Other languages

English (en)

Inventor

Gale Eugene Smith

James T Mattews

Edwin D Kilbourne

Bert E Johannson

Bethanie E Wilkinson

Andrei I Voznesensky

Craig S Hackett

Franklin Volvovitz

Original Assignee

Protein Sciences Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-04-28

Filing date

1996-04-26

Publication date

2003-07-15

1996-04-26 Application filed by Protein Sciences Corp filed Critical Protein Sciences Corp

2003-07-15 Application granted granted Critical

2003-07-15 Publication of ATE243530T1 publication Critical patent/ATE243530T1/de

Links

241000700605 Viruses Species 0.000 title abstract 11
229960005486 vaccine Drugs 0.000 title abstract 3
108010006232 Neuraminidase Proteins 0.000 abstract 3
102000005348 Neuraminidase Human genes 0.000 abstract 3
239000000185 hemagglutinin Substances 0.000 abstract 3
101710091045 Envelope protein Proteins 0.000 abstract 2
101710154606 Hemagglutinin Proteins 0.000 abstract 2
101710093908 Outer capsid protein VP4 Proteins 0.000 abstract 2
101710135467 Outer capsid protein sigma-1 Proteins 0.000 abstract 2
101710176177 Protein A56 Proteins 0.000 abstract 2
101710188315 Protein X Proteins 0.000 abstract 2
102100021696 Syncytin-1 Human genes 0.000 abstract 2
230000002163 immunogen Effects 0.000 abstract 2
229960003971 influenza vaccine Drugs 0.000 abstract 2
102000007644 Colony-Stimulating Factors Human genes 0.000 abstract 1
108010071942 Colony-Stimulating Factors Proteins 0.000 abstract 1
102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 abstract 1
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 abstract 1
241000700588 Human alphaherpesvirus 1 Species 0.000 abstract 1
241000701074 Human alphaherpesvirus 2 Species 0.000 abstract 1
241000701044 Human gammaherpesvirus 4 Species 0.000 abstract 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 abstract 1
241000712079 Measles morbillivirus Species 0.000 abstract 1
208000002606 Paramyxoviridae Infections Diseases 0.000 abstract 1
241000725643 Respiratory syncytial virus Species 0.000 abstract 1
239000002671 adjuvant Substances 0.000 abstract 1
239000000427 antigen Substances 0.000 abstract 1
102000036639 antigens Human genes 0.000 abstract 1
108091007433 antigens Proteins 0.000 abstract 1
239000012634 fragment Substances 0.000 abstract 1
239000002243 precursor Substances 0.000 abstract 1
102000004169 proteins and genes Human genes 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1
241000712461 unidentified influenza virus Species 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A61K39/165—Mumps or measles virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A61K39/25—Varicella-zoster virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
- C12N2710/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Virology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Mycology (AREA)
Immunology (AREA)
Microbiology (AREA)
Pulmonology (AREA)
Communicable Diseases (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Oncology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

AT96913234T 1995-04-28 1996-04-26 Virus impfstoff ATE243530T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/430,971 US5976552A (en)	1995-04-28	1995-04-28	Virus vaccines
PCT/US1996/005904 WO1996033738A1 (en)	1995-04-28	1996-04-26	Improved virus vaccines

Publications (1)

Publication Number	Publication Date
ATE243530T1 true ATE243530T1 (de)	2003-07-15

Family

ID=23709884

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT96913234T ATE243530T1 (de)	1995-04-28	1996-04-26	Virus impfstoff

Country Status (11)

Country	Link
US (2)	US5976552A (de)
EP (1)	EP0830141B1 (de)
CN (1)	CN1141977C (de)
AT (1)	ATE243530T1 (de)
AU (1)	AU696690B2 (de)
CA (1)	CA2222283C (de)
DE (1)	DE69628834T2 (de)
DK (1)	DK0830141T3 (de)
ES (1)	ES2201184T3 (de)
PT (1)	PT830141E (de)
WO (1)	WO1996033738A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6485729B1 (en) *	1993-09-13	2002-11-26	Protein Sciences Corporation	Neuraminidase-supplemented compositions
US6495185B1 (en) *	1996-10-31	2002-12-17	Slk Foundation	Flavoring composition, production and use thereof
AU7126998A (en) *	1997-04-16	1998-11-11	Connaught Laboratories Inc.	Anti-influenza compositions supplemented with neuraminidase
NZ512980A (en) *	1998-12-17	2003-07-25	Aventis Pasteur	Multivalent immunogenic composition containing RSV subunit composition and influenza virus preparation
AT407958B (de) *	1999-02-11	2001-07-25	Immuno Ag	Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
AR025750A1 (es) *	1999-09-24	2002-12-11	Smithkline Beecham Biolog	Vacunas
US7122018B2 (en)	2000-12-26	2006-10-17	Sensormedics Corporation	Device and method for treatment of wounds with nitric oxide
DE60332358D1 (de) *	2002-09-09	2010-06-10	Hanall Pharmaceutical Co Ltd	Protease-resistente modifizierte interferon alpha polypeptide
AU2003284246A1 (en)	2002-10-16	2004-05-04	Samuel F. Hunter	Method for treatment of demyelinating central nervous system disease using gm-csf
US20060110740A1 (en) *	2003-01-20	2006-05-25	Julia Hurwitz	Use of sendai virus as a human parainfluenza vaccine
TWI295995B (en) *	2003-08-19	2008-04-21	Academia Sinica	Protein isolation
EP1841785A2 (de)	2005-01-19	2007-10-10	Vaxinnate Corporation	Zusammensetzungen, die pathogen-assoziierte molekulare muster und antigene enthalten und deren verwendung zur stimulation des immunsystems
GB0504436D0 (en) *	2005-03-03	2005-04-06	Glaxosmithkline Biolog Sa	Vaccine
US11865172B2 (en)	2005-04-21	2024-01-09	University Of Florida Research Foundation, Inc.	Materials and methods for respiratory disease control in canines
CN101248186A (zh) *	2005-05-23	2008-08-20	瓦克辛公司	不含腺病毒的重组腺病毒载体的快速生产
WO2007057763A2 (en) *	2005-11-18	2007-05-24	Pulmonox Technologies Corporation	Nitric oxide as an anti-viral agent, vaccine and vaccine adjuvant
TWI477602B (zh)	2006-02-09	2015-03-21	Educational Foundation Jichi Medical Univ	Novel viral vector
US9333249B2 (en)	2006-02-09	2016-05-10	Educational Foundation Jichi Medical University	Recombinant baculovirus vaccine
EP3011969A1 (de)	2006-03-07	2016-04-27	Vaxinnate Corporation	Zusammensetzungen mit hämagglutinin, verfahren zur herstellung und verfahren zur verwendung davon
EP2139908A4 (de) *	2007-03-12	2011-02-16	Antigen Express Inc	Li-suppression unter beteiligung von li-rnai in der krebs-immuntherapie
CN101307310B (zh) *	2007-05-15	2012-08-08	康泰生医科技股份有限公司	具有提高产率及免疫原性的重组蛋白质表达系统
EP2014279A1 (de) *	2007-06-22	2009-01-14	Pevion Biotech AG	Virosomen enthaltend Haemagglutinin, das von über Zelllinien hergestellten Influenza-Viren stammt, Zusammensetzungen, Herstellungsverfahren, Verwendung davon
WO2009128952A2 (en)	2008-04-18	2009-10-22	Vaxinnate Corporation	Compositions of papillomavirus proteins and methods of use
WO2010144797A2 (en)	2009-06-12	2010-12-16	Vaccine Technologies, Incorporated	Influenza vaccines with enhanced immunogenicity and uses thereof
JP2013516469A (ja) *	2010-01-06	2013-05-13	ヴァクシネイトコーポレイション	高齢者に保護免疫を提供するための方法及び組成物
CN114010776A (zh)	2010-06-09	2022-02-08	疫苗技术股份有限公司	用于增强抗逆转录病毒治疗的hiv感染者的治疗性免疫
BR112013010830A2 (pt) *	2010-11-02	2017-12-12	Hector Manuel Zepeda Lopez	vacina inovadoras contra o vírus da influenza pandêmica a/h1n1
CA2829916C (en)	2011-03-21	2019-08-20	Vaxin Inc.	Intranasal administration of an adenovirus vector to induce a protective immune response to an inhalation pathogen
US8932598B2 (en)	2012-08-28	2015-01-13	Vaxinnate Corporation	Fusion proteins and methods of use
WO2017123652A1 (en)	2016-01-11	2017-07-20	Verndari, Inc.	Microneedle compositions and methods of using same
CN105854009A (zh) *	2016-05-03	2016-08-17	重庆三杰众鑫生物工程有限公司	应用番鸭肝炎病毒制备灭活疫苗的制备方法
MX2019014943A (es)	2018-12-12	2020-08-06	Cambridge Tech Llc	Vacuna universal contra la gripe.
EP4426346A1 (de)	2021-11-05	2024-09-11	Sanofi Pasteur, Inc.	Multivalente influenzaimpfstoffe mit rekombinantem hämagglutinin und neuraminidase und verfahren zur verwendung davon
EP4426345A1 (de)	2021-11-05	2024-09-11	Sanofi	Multivalente hybridinfluenzaimpfstoffe mit hämagglutinin und neuraminidase sowie verfahren zur verwendung davon

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2667245B1 (fr) *	1990-10-01	1992-11-06	Rhone Merieux	Association vaccinale contre les pathogenes infectieux.
CA2139756A1 (en) *	1992-07-08	1994-01-20	Eric M. Bonnem	Use of gm-csf as a vaccine adjuvant

1995
- 1995-04-28 US US08/430,971 patent/US5976552A/en not_active Expired - Lifetime
1996
- 1996-04-26 AT AT96913234T patent/ATE243530T1/de active
- 1996-04-26 CN CNB961950706A patent/CN1141977C/zh not_active Expired - Fee Related
- 1996-04-26 DE DE69628834T patent/DE69628834T2/de not_active Expired - Lifetime
- 1996-04-26 EP EP96913234A patent/EP0830141B1/de not_active Expired - Lifetime
- 1996-04-26 CA CA2222283A patent/CA2222283C/en not_active Expired - Fee Related
- 1996-04-26 DK DK96913234T patent/DK0830141T3/da active
- 1996-04-26 AU AU56312/96A patent/AU696690B2/en not_active Revoked
- 1996-04-26 WO PCT/US1996/005904 patent/WO1996033738A1/en not_active Ceased
- 1996-04-26 PT PT96913234T patent/PT830141E/pt unknown
- 1996-04-26 ES ES96913234T patent/ES2201184T3/es not_active Expired - Lifetime
1999
- 1999-01-22 US US09/235,901 patent/US20020071848A1/en not_active Abandoned

Also Published As

Publication number	Publication date
DK0830141T3 (da)	2003-10-20
WO1996033738A1 (en)	1996-10-31
DE69628834T2 (de)	2004-05-06
PT830141E (pt)	2003-11-28
AU696690B2 (en)	1998-09-17
CA2222283A1 (en)	1996-10-31
US5976552A (en)	1999-11-02
US20020071848A1 (en)	2002-06-13
CN1141977C (zh)	2004-03-17
CN1189103A (zh)	1998-07-29
DE69628834D1 (de)	2003-07-31
EP0830141B1 (de)	2003-06-25
ES2201184T3 (es)	2004-03-16
HK1013595A1 (en)	1999-09-03
EP0830141A1 (de)	1998-03-25
AU5631296A (en)	1996-11-18
CA2222283C (en)	2015-02-03

Legal Events

Date

Code

Title

Description

2004-02-15

UEP

Publication of translation of european patent specification

Ref document number: 0830141

Country of ref document: EP

Publication	Publication Date	Title
DE69628834D1 (de)	2003-07-31	Virus impfstoff
Hashigucci et al.	1996	Antibody responses in volunteers induced by nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin
US5723130A (en)	1998-03-03	Adjuvants for vaccines against respiratory syncytial virus
AU2684792A (en)	1993-05-21	Porcine reproductive respiratory syndrome vaccine and diagnostic
FI102616B1 (fi)	1999-01-15	Menetelmä rokotteen valmistamiseksi ihmisen parainfluenssa-viruksen tyyppiä 3 varten ja menetelmässä käytettävä ilmentämisjärjestelmä
Kodihalli et al.	1994	A type-specific avian influenza virus subunit vaccine for turkeys: induction of protective immunity to challenge infection
RU2000116260A (ru)	2002-06-27	Вакцины с адъювантом ltb
DK0584348T3 (da)	2005-09-19	Genetisk vaccine mod immundefektvirusser
EA200900784A1 (ru)	2009-12-30	Вакцины, включающие антиген из четырех штаммов вируса гриппа
CA2181832A1 (en)	1995-08-03	Immunization by inoculation of dna transcription unit
BR9610590A (pt)	2000-10-24	Glicoproteìnas e vacinas de vìrus parainfluenza
ES2127294T3 (es)	1999-04-16	Vacunas del virus de la inmunodeficiencia anti-felino (fiv).
ATE101200T1 (de)	1994-02-15	Impfstoffe gegen menschliche respiratorische viren.
AU3887695A (en)	1996-05-02	Interleukin-12 as an adjuvant for paramyxoviridae vaccines
Downie	1970	Neuraminidase-and hemagglutinin-inhibiting antibodies in serum and nasal secretions of volunteers immunized with attenuated and inactivated influenza B/Eng/13/65 virus vaccines
FI890603A0 (fi)	1989-02-08	Menetelmä HIV-hiukkasimmunogeenin ja sen vasta-aineen valmistamiseksi
GB1229888A (de)	1971-04-28
DE69720024D1 (de)	2003-04-24	Immunisierungsverfahren in zwei schritten gegen pyramyxoviridae-viren unter verwendung abgeschwächter viraler stämme und preparation von proteinuntereinheiten
Liashenko et al.	1999	Measles IgA in the nasal washings of adult volunteers and children immunized intranasally with measles vaccine L-16
BR9909076A (pt)	2000-12-05	Vìrus atenuado do sarampo, recombinantemente gerado, isolado, vìrus do sarampo, vìrus sincicial respiratório humano (rsv), subgrupo b, atenuado, recombinantemente gerado, isolado, o rsv, subgrupo b, vacina processo para imunização de um indivìduo para induzir proteção contra vìrus do sarampo, processo para imunização de um indivìduo para induzir proteção contra o rsv, subgrupo b, composição, processo para produção de vìrus do sarampo infeccioso atenuado, processo para produção de rsv infeccioso atenuado subgrupo b
WO2001083528A3 (en)	2002-04-25	Nucleic acid immunization
PT100460A (pt)	1993-08-31	Partiiculas derivadas de virus de herpes e vacinas que as contem
GB1413401A (en)	1975-11-12	Influenza vaccine
Trudel et al.	1990	Efficient intranasal vaccination of mice against human respiratory syncytial virus with an experimental iscoms subunit vaccine
Teokhorova et al.	1984	Clinical and immunological studies in the use of an experimental lot of hepatitis B vaccine.